GENETOBE INC
Ann Arbor, MI · Biotech · Private
miCas9-based gene editing therapy for CLRN1 gene correction in Usher syndrome type 3A retinal degeneration
genetobe.com →- Grants
- $1.4M
- 5 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development of miCas9 mediated gene editing therapies for cystic fibrosis | $246,100 | |
| Federal grant | Department of Health and Human Services · Phase II · Genome Editing Therapy for Usher Syndrome Type 3 | $289,895 | |
| Federal grant | Department of Health and Human Services · Phase I · Genome Editing Therapy for Usher Syndrome Type 3 | $289,895 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing novel Type 1 CRISPR tools for gene editing therapy | $293,319 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Selective SGLT-1 Inhibitors for Adjunctive Therapy for Cystic Fibrosis Associated Metabolic Diseases | $306,779 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3037 | OPSIN BIOTHERAPEUTICS INC. | — | — |
| 3038 | TRANSIRA THERAPEUTICS LLC | — | — |
| 3039 | ECMedical LLC | — | — |
| 3040 | GENETOBE INC | — | — |
| 3041 | DISCOVERY GENOMICS, INC. | — | — |
| 3042 | TOPOGENE, INC. | — | — |
| 3043 | AIVOCODE, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.